{"schema_version":"1.0","type":"article","title":"骨折價 瘦瘦針來了，每月420塊台幣","url":"https://drugnews.com.tw/articles/2026-04-06-420.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-06-420.md","lang":"zh-Hant","date":"2026-04-06","publish_at":"2026-04-06T10:30:00+08:00","updated_at":"2026-04-06","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","BD","臨床數據","生技投資"],"summary":"2026 年 3 月，semaglutide （瘦瘦針）在印度迎來一個足以寫進產業教科書的時刻。","key_points":[],"facts":[],"sections":["當 semaglutide （瘦瘦針）在印度跌到每月 14 美元，真正被顛覆的不是減重藥價格，而是整個 GLP-1 市場的商業邏輯","價格崩塌，不只是便宜，而是價格體系被整個改寫","真正的戰爭，不只是價格，而是整套產品系統","價格放開之後，灰色需求與監管壓力也一起湧上來","印度不是局部事件，而是全球 GLP-1 專利懸崖的第一場壓力測試","Novo 與 Lilly 早就聞到風向，但專利到期的洪流很難真正擋下","真正被顛覆的，不是價格，而是 GLP-1 的產業定位"],"references":[{"title":"各公司官網＆公開資料","source":"","date":"","url":""},{"title":"Salve,P.et al.India is launching cheap,weight-loss drugs and Novo Nordisk is betting on its brands to stay on top.CNBC.23.03.2026.","source":"","date":"","url":""},{"title":"Sanjay,S.Ozempic Copies at$14 in India as Novo Patent Expires.Bloomberg.20.03.2026.","source":"","date":"","url":""},{"title":"Generic Ozempic to cost Rs 1,290 in India:A game changer in the fight against obesity?Firstpost.20.03.2026.","source":"","date":"","url":""},{"title":"Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India.CNBC.19.03.2026.","source":"","date":"","url":""},{"title":"Dunleavy,K.With Novo's semaglutide going off patent,Indian drugmakers set to launch their cheaper generics.FiercePharma.20.03.2026.","source":"","date":"","url":""},{"title":"Novo to track generic surge as semaglutide goes off patent.India Times.21.03.2026.","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：骨折價 瘦瘦針來了，每月420塊台幣（圖 1）","url":"https://drugnews.com.tw/assets/articles/420/dcard-01.webp"},{"alt":"Dcard 原圖：骨折價 瘦瘦針來了，每月420塊台幣（圖 2）","url":"https://drugnews.com.tw/assets/articles/420/dcard-02.webp"},{"alt":"Dcard 原圖：骨折價 瘦瘦針來了，每月420塊台幣（圖 3）","url":"https://drugnews.com.tw/assets/articles/420/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/420/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-06）。骨折價 瘦瘦針來了，每月420塊台幣。https://drugnews.com.tw/articles/2026-04-06-420.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-06-420-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}